SABS.NASDAQSab Biotherapeutics, INC

Form 4: SAB Biotherapeutics CEO Samuel Reich Acquires Stock Options

Sentiment:

SEC Form 4 Filing

📋All filings for Sab Biotherapeutics, INC
🔒Login to Follow

Samuel Reich, CEO and Executive Chairman of SAB Biotherapeutics, acquired stock options for 35,700 shares on July 15, 2024.

Summary

  • Samuel J. Reich, CEO and Executive Chairman of SAB Biotherapeutics, filed a Form 4 on July 17, 2024.
  • The filing reports a transaction that occurred on July 15, 2024, where Reich acquired stock options for 35,700 shares of SAB Biotherapeutics.
  • The exercise price of the stock options is $2.9.
  • The options vest 25% on July 15, 2025, and then in equal monthly installments over three years, ending July 15, 2028.
  • The options expire on July 15, 2034.
  • The grant was made under the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing about stock option grants. The CEO's acquisition could be interpreted as a slightly positive signal.

Positives

  • The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

  • The stock option grant could potentially align the CEO's interests with those of the shareholders.

Key Dates

DateDescription
07/15/2024Date of the stock option grant.
07/15/202525% of the stock options vest.
07/15/2028End of the three-year vesting period.
07/15/2034Expiration date of the stock options.
07/17/2024Date the Form 4 was filed.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.